Алкогольная болезнь печени: современное состояние проблемы


Цитировать

Полный текст

Аннотация

Аннотация. В обзоре литературы представлены современные взгляды на диагностику и лечение алкогольной болезни печени (АБП). Приведены данные о генетических маркерах, ассоциированных с развитием АБП и алкогольной зависимостью. Подробно обсуждены механизмы поражения печени в рамках рассматриваемого заболевания. Обосновываются показания к применению преднизолона и пентоксифиллина при алкогольном гепатите. Рассмотрены терапевтические подходы к лечению различных форм АБП.

Полный текст

Алкогольная болезнь печени: современное состояние проблемы. - Аннотация. В обзоре литературы представлены современные взгляды на диагностику и лечение алкогольной болезни печени (АБП). Приведены данные о генетических маркерах, ассоциированных с развитием АБП и алкогольной зависимостью. Подробно обсуждены механизмы поражения печени в рамках рассматриваемого заболевания. Обосновываются показания к применению преднизолона и пентоксифиллина при алкогольном гепатите. Рассмотрены терапевтические подходы к лечению различных форм АБП.
×

Об авторах

И В Маев

ГБОУ ВПО "Московский государственный медико-стоматологический университет им. А.И. Евдокимова" Минздрава России

Д Т Абдурахманов

ГБОУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздрава России

Д Н Андреев

ГБОУ ВПО "Московский государственный медико-стоматологический университет им. А.И. Евдокимова" Минздрава России

Email: dna-mit8@mail.ru

Д Т Дичева

ГБОУ ВПО "Московский государственный медико-стоматологический университет им. А.И. Евдокимова" Минздрава России

Список литературы

  1. Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol 2011; 45: 714-719.
  2. Rehm J., Mathers C., Popova S. et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009; 373 (9682): 2223-2233.
  3. Заграев Г.Г. Алкоголизм и пьянство в России. Пути выхода из кризисной ситуации. Социол исслед 2009; 8: 74-84.
  4. Lieber C.S., Jones D.P., Decarli L.M. Effects of Prolonged Ethanol Intake: Production of Fatty Liver Despite Adequate Diets. J Clin Invest 1965; 44: 1009-1021.
  5. Helman R.A., Temko M.H., Nye S.W., Fallon H.J. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med 1971; 74 (3): 311-321.
  6. Гастроэнтерология. Национальное руководство: краткое издание. Под. ред В.Т. Ивашкина, Т.Л. Лапиной. М: ГЭОТАР-Медиа 2011; 480.
  7. Bruha R., Dvorak K., Petrtyl J. Alcoholic liver disease. World J Hepatol 2012; 4 (3): 81-90.
  8. Menon K.V., Gores G.J., Shah V.H. Pathogenesis, diagnosis, and treatment of alcoholic liver disease. Mayo Clin Proc 2001; 76 (10): 1021-1029.
  9. Bosetti C., Levi F., Lucchini F. et al. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007; 46 (5): 827-839.
  10. Carithers R.L., McClain C. Alcoholic liver disease. In: Feldman M., Friedman L.S., Brandt L.J. Feldman: Sleisinger & Fordtran’s Gastrointestinal and Liver Disease. 9th ed. Philadelphia, Pa: Saunders Elsevier; 2010: chap 84.
  11. Becker U., Deis A., Sørensen T.I. et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996; 23 (5): 1025-1029.
  12. O’Shea R.S., Dasarathy S., McCullough A.J. Alcoholic liver disease. Hepatology 2010; 51: 307-328.
  13. Wilfred de Alwis N.M., Day C.P. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007; 27: 44-54.
  14. Juran B.D., Lazaridis K.N. Genomics and complex liver disease: Challenges and opportunities. Hepatology 2006; 44: 1380-1390.
  15. Whitfield J.B. Meta-analysis of the effects of alcohol dehydrogenase genotype on alcohol dependence and alcoholic liver disease. Alcohol Alcohol 1997; 32: 613-619.
  16. Valenti L., De Feo T., Fracanzani A.L. et al. Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients. Alcohol Alcohol 2004; 39: 276-280.
  17. Trépo E., Gustot T., Degré D. et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol 2011; 55 (4): 906-912.
  18. Arteel G., Marsano L., Mendez C. et al. Advances in alcoholic liver disease. Best Pract Res Clin Gastroenterol 2003; 17: 625-647.
  19. Baldini M., Lohman I.C., Halonen M. et al. A polymorphism in the 5' flankingregion of the CD14 gene is associated with circulating soluble CD14 levelsand with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20: 976-983.
  20. Siu L., Foont J., Wands J.R. Hepatitis C virus and alcohol. Semin Liver Dis 2009; 29 (2): 188-199.
  21. Raynard B., Balian A., Fallik D. et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002; 35 (3): 635-638.
  22. Naveau S., Giraud V., Borotto E. et al. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25 (1): 108-111.
  23. Corrao G., Lepore A.R., Torchio P. et al. The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease. Eur J Epidemiol 1994; 10 (6): 657-664.
  24. Pessione F., Ramond M.J., Njapoum C. et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001; 34 (1): 121-125.
  25. Rang H.P., Dale M.M., Ritter J.M., Flower R.J. Rang and Dale’s pharmacology. London: Elsevier Churchill Livingstone; 2007.
  26. Arteel G.E. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology 2003; 124: 778-790.
  27. Farfán Labonne B.E., Gutiérrez M., Gómez-Quiroz L.E. et al. Acetaldehyde-induced mitochondrial dysfunction sensitizes hepatocytes to oxidative damage. Cell Biol Toxicol 2009; 25 (6): 599-609.
  28. Setshedi M., Wands J.R., Monte S.M. Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev 2010; 3 (3): 178-185.
  29. Thiele G.M., Worrall S., Tuma D.J. et al. The chemistry and biological effects of malondialdehyde-acetaldehyde adducts. Alcohol Clin Exp Res 2001; 25 (5 Suppl ISBRA): 218S-224S.
  30. Mello T., Ceni E., Surrenti C., Galli A. Alcohol induced hepatic fibrosis: role of acetaldehyde. Mol Aspects Med 2008; 29 (1-2): 17-21.
  31. Arteel G., Marsano L., Mendez C. et al. Advances in alcoholic liver disease. Best Pract Res Clin Gastroenterol 2003; 17 (4): 625-647.
  32. Gao B., Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141 (5): 1572-1585.
  33. You M., Fischer M., Deeg M.A., Crabb D.W. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem 2002; 277 (32): 29342-29347.
  34. Peng Z., Borea P.A., Varani K. et al. Adenosine signaling contributes to ethanol-induced fatty liver in mice. J Clin Invest 2009; 119 (3): 582-594.
  35. Jeong W.I., Osei-Hyiaman D., Park O. et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 2008; 7 (3): 227-235.
  36. Ji C., Deng Q., Kaplowitz N. Role of TNF-alpha in ethanol-induced hyperhomocysteinemia and murine alcoholic liver injury. Hepatology 2004; 40 (2): 442-451.
  37. You M., Matsumoto M., Pacold C.M. et al. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 2004; 127 (6): 1798-1808.
  38. You M., Liang X., Ajmo J.M., Ness G.C. Involvement of mammalian sirtuin 1 in the action of ethanol in the liver. Am J Physiol Gastrointest Liver Physiol 2008; 294 (4): G892-G898.
  39. You M., Rogers C.Q. Adiponectin: a key adipokine in alcoholic fatty liver. Exp Biol Med (Maywood) 2009; 234 (8): 850-859.
  40. Horiguchi N., Wang L., Mukhopadhyay P. et al. Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology 2008; 134 (4): 1148-1158.
  41. Wagner M., Zollner G., Trauner M. Nuclear receptors in liver disease. Hepatology 2011; 53 (3): 1023-1034.
  42. Galli A., Pinaire J., Fischer M. et al. The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism. A novel mechanism for the development of ethanol-induced fatty liver. J Biol Chem 2001; 276 (1): 68-75.
  43. Lu Y., Zhuge J., Wang X. et al. Cytochrome P450 2E1 contributes to ethanol-induced fatty liver in mice. Hepatology 2008; 47 (5): 1483-1494.
  44. McClain C.J., Song Z., Barve S.S. et al. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 287 (3): G497-G502.
  45. Purohit V., Bode J.C., Bode C. et al. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol 2008; 42 (5): 349-361.
  46. Wheeler M.D. Endotoxin and Kupffer cell activation in alcoholic liver disease. Alcohol Res Health 2003; 27 (4): 300-306.
  47. Luedde T., Schwabe R.F. NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011; 8 (2): 108-118.
  48. Lemmers A., Moreno C., Gustot T. et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009; 49 (2): 646-657.
  49. Seki E., De Minicis S., Osterreicher C.H. et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13 (11): 1324-1332.
  50. Абдурахманов Д.Т. Алкогольный гепатит. Клин гепатол 2008; 4 (2): 3-10.
  51. Ивашкин В.Т. Болезни печени и желчевыводящих путей. Руководство для врачей. 2-е изд. М: Издательский дом М-Вести 2005.
  52. Маев И.В., Абдурахманов Д.Т., Дичева Д.Т. и др. Алкогольная болезнь печени. Клин гепатол 2012; 8 (2): 33-40.
  53. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57 (2): 399-420.
  54. Лазебник Л.Б., Дроздов В.Н. Заболевания органов пищеварения у пожилых. М: Анахарсис 2003.
  55. Bradley K.A., DeBenedetti A.F., Volk R.J. et al. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res 2007; 31 (7): 1208-1217.
  56. Sorbi D., Boynton J., Lindor K.D. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94 (4): 1018-122.
  57. Soresi M., Magliarisi C., Campagna P. et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 2003; 23 (2C): 1747-1753.
  58. Marrero J.A., Su G.L., Wei W. et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003; 37 (5): 1114-1121.
  59. Elphick D.A., Dube A.K., McFarlane E. et al. Spectrum of liver histology in presumed decompensated alcoholic liver disease. Am J Gastroenterol 2007; 102 (4): 780-788.
  60. Lefkowitch J.H. Morphology of alcoholic liver disease. Clin Liver Dis 2005; 9 (1): 37-53.
  61. Maddrey W.C., Boitnott J.K., Bedine M.S. et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75 (2): 193-199.
  62. Forrest E.H., Evans C.D., Stewart S. et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54 (8): 1174-1179.
  63. Dunn W., Jamil L.H., Brown L.S. et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41: 353-358.
  64. Диетология. Руководство. 3-е изд. Под ред. А.Ю.Баранов­ского. СПб: Питер 2008.
  65. Смолянский Б.Л., Лифляндский В.Г. Диетология. Новейший справочник для врачей. СПб: Сова, М: Эксмо 2003.
  66. Mathurin P., Mendenhall C.L., Carithers R.L. et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002; 36: 480-487.
  67. Ramond M.-.J, Poynard T., Rueff B. et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 362: 507-512.
  68. Forrest E.H., Morris A.J., Stewart S. et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007; 56 (12): 1743-1746.
  69. Mathurin P., Abdelnour M., Ramond M.J. et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003; 38: 1363-1369.
  70. Louvet A., Naveau S., Abdelnour M. et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45: 1348-1354.
  71. Deree J., Martins J.O., Melbostad H. et al. Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition. Clinics (Sao Paulo) 2008; 63 (3): 321-328.
  72. McHutchison J.G., Draguesku R.B. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology 1991; 14: 96A.
  73. Akriviadis E., Botla R., Briggs W. et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648.
  74. Boetticher N.C., Peine C.J., Kwo P. et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135 (6): 1953-1960.
  75. Mato J.M., Camara J., Fernandez de Paz J. et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30: 1081-1089.
  76. Rambaldi A., Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2006; (2): CD002235.
  77. Маев И. Дичева Д., Андреев Д., Пенкина Т. Урсодезоксихолевая кислота в терапии алкогольной болезни печени. Врач 2012; 10: 52-55.
  78. Pelletier G., Roulot D., Davion T. et al. URSOMAF Group. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice. Hepatology 2003; 37 (4): 887-892.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2014

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Адрес издателя

  • 127055, г. Москва, Алабяна ул., 13, корп.1

Адрес редакции

  • 127055, г. Москва, Алабяна ул., 13, корп.1

По вопросам публикаций

  • +7 (926) 905-41-26
  • editor@ter-arkhiv.ru

По вопросам рекламы

  • +7 (495) 098-03-59

 

  


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах